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It has been hypothesized that drugs that serve as substrates for dopamine (DA) and 
norepinephrine (NE) transporters may be more suitable medications for cocaine dependence 
than drugs that inhibit DA and NE uptake by binding to transporters. Previous studies have 
shown that the DA/NE releaser d-amphetamine can decrease cocaine self-administration in 
preclinical and clinical studies. The present study examined the effects of methylphenidate 
(MPD), a DA uptake inhibitor, for its ability to decrease cocaine self-administration under 
conditions designed to reflect clinically relevant regimens of cocaine exposure and 
pharmacotherapy. Each morning, rhesus monkeys pressed a lever to receive food pellets under 
a fixed-ratio 50 schedule of reinforcement; cocaine was self-administered under a progressive-
ratio schedule of reinforcement in the evening. After cocaine (0.003-0.56 mg/kg per injection, 
i.v.) dose-response curves were determined, self-administration sessions were suspended and 
MPD (0.003-0.0056 mg/kg per hr, i.v. or 1.0-9.0 mg/kg p.o., b.i.d.) was administered for several 
weeks. A cocaine self-administration session was conducted every 7 days. When a MPD dose 
was reached that either persistently decreased cocaine self-administration or produced 
disruptive effects, the cocaine dose-effect curve was re-determined. In most cases, MPD 
treatment either produced behaviorally disruptive effects or increased cocaine self-
administration; it took several weeks for these effects to dissipate. These data are consistent 
with the largely negative results of clinical trials with MPD. In contrast to the positive effects with 
the monoamine releaser d-amphetamine under identical conditions, these results do not support 






Cocaine abuse persists as a major public health problem for which no pharmacotherapy has 
proven to be sufficiently effective (Vocci and Ling, 2005). The success of methadone and 
nicotine replacement therapies in the treatment of opiate and nicotine addiction, respectively, 
has encouraged efforts to develop an indirect dopamine (DA) receptor agonist to treat stimulant 
abuse (Grabowski et al., 2004; Herin et al., 2010; Rush and Stoops, 2012). For example, d-
amphetamine, a monoamine releaser, has shown positive effects in human cocaine abusers 
(Grabowski et al., 2004) and in rodent (Chiodo et al., 2008; Chiodo and Roberts, 2009; 
Thomsen et al., 2013) and monkey (Negus, 2003; Negus and Mello, 2003; Czoty et al., 2010, 
2011) models. While efforts are ongoing to develop novel DA indirect agonists for this purpose 
(e.g., Carroll et al., 1999; Platt et al., 2002; Lile and Nader, 2003; Rothman et al., 2005; Howell 
and Kimmel, 2008), one currently approved for use in humans drug is methylphenidate (MPD), 
a DA and norepinephrine (NE) transporter inhibitor used to treat attention-deficit hyperactivity 
disorder (ADHD; Holmes, 1995). MPD has pharmacological and behavioral effects that overlap 
considerably with those of cocaine (e.g., Bergman et al., 1989; Volkow et al., 1999).  
Despite its potential suitability as a medication for cocaine dependence, interactions 
between MPD and the abuse-related effects of cocaine are incompletely understood. Two 
laboratory studies in humans have reported decreased subjective and reinforcing effects of 
cocaine in individuals maintained on oral MPD (Collins et al., 2006; Winhusen et al., 2006). 
Results of clinical trials, however, have been mixed in terms of the ability of MPD to decrease 
cocaine-positive urines (Grabowski et al., 1997; Schubiner et al., 2002; Somoza et al., 2004; 
Levin et al., 2007). Possible confounding variables in these studies include the 
presence/absence of ADHD and relatively small sample sizes. Studies in laboratory animals 
may provide a more thorough, unconfounded understanding of whether MPD can alter ongoing 
cocaine self-administration. However, most previous laboratory animal studies have examined 





Andersen et al., 2002; Thanos et al., 2007; Gill et al., 2012). Although clinically important with 
respect to the long-term effects of MPD as an ADHD treatment in adolescents, such studies do 
not address whether MPD has effects consistent with a useful pharmacotherapy for cocaine 
dependence. Only one study has examined whether administration of MPD alters ongoing 
cocaine self-administration (Hiranita et al., 2009). In that experiment, MPD was administered 
acutely prior to behavioral sessions during which rats self-administered cocaine under a 5-
response fixed-ratio (FR 5) schedule of reinforcement. MPD dose-dependently shifted the 
cocaine dose-response curve leftward, indicating an increase in potency of cocaine to function 
as a reinforcer. Thus, one objective of this study was to expand the study of MPD in a 
nonhuman primate model of cocaine abuse. 
The present study examined the effects of chronically administered MPD on cocaine 
self-administration under a progressive-ratio (PR) schedule of reinforcement in rhesus monkeys. 
We used an approach to testing putative pharmacotherapies that we recently described in the 
context of assessing d-amphetamine (Czoty et al., 2011). Briefly, this model is designed to 
better incorporate clinically relevant variables including (1) subjects with an extensive history of 
cocaine self-administration, (2) concurrent, daily monitoring of food-reinforced responding and 
other observable behaviors that may model side effects, (3) an individual-subject design in 
which MPD dose was adjusted for each monkey based on observed effects (or lack thereof) on 
cocaine-reinforced responding, (4) assessment of MPD effects on self-administration of a range 
of cocaine doses and (5) suspension of access to cocaine during MPD treatment. This latter 
feature was implemented to model the scenario in which an addict refrains from using cocaine 
during a brief period at the outset of treatment. Rather than assessing the direct interactions of 
MPD on daily cocaine self-administration, the effect on cocaine reinforcement was assessed 






In a previous study under the same conditions, the monoamine releaser d-amphetamine 
reliably produced sustained reductions in cocaine self-administration in the absence of long-
lasting adverse effects (Czoty et al., 2011). An additional reason for examining MPD in the 
present study was the ability to compare the results of these two DA indirect agonists and 
provide data relevant to the hypothesis that drugs that serve as substrates for DA and NE 
transporters (i.e., “releasers”) may be more suitable pharmacotherapies for cocaine 
dependence than drugs that block DA and NE transporters (cf. Negus et al., 2009a,b). In 
addition to examining the effects of chronic MPD administered intravenously, the effects of daily 
oral MPD was studied. Finally, another goal of this study was to use the results to further assess 




Subjects and Apparatus. Subjects were five adult male rhesus monkeys (Macaca mulatta), 
each prepared with a chronic indwelling venous catheter and subcutaneous vascular access 
port (Access Technologies, Skokie, IL) under sterile surgical conditions as described previously 
(Czoty et al., 2006). Monkeys had between 6 and 15 months experience self-administering 
cocaine at the outset of these studies, with the exception of R-1429 who had self-administered 
cocaine for over three years. Monkeys were housed individually in sound-attenuating chambers 
(0.91 x 0.91 x 0.91 m; Plas Labs, Lansing, MI). The front wall of each cubicle was constructed of 
Plexiglas to allow the monkey visual access to the laboratory. Each cubicle was equipped with 
two response levers (BRS/LVE, Beltsville, MD). Four stimulus lights, alternating white and red, 
were located in a horizontal row above each lever. A receptacle located between the levers was 
connected via tygon tubing to a pellet dispenser located outside the chamber for response-
contingent delivery of food pellets. Each animal was fitted with a stainless-steel restraint 





cubicle. A peristaltic infusion pump (Cole-Parmer Instrument Co., Vernon Hills, IL) was located 
on the top of the chamber for delivering injections at a rate of approximately 1.5 ml/10 sec. 
Monkeys received fresh fruit, peanuts and vegetables several days per week and water was 
available ad libitum. Animal housing and handling and all experimental procedures were 
performed in accordance with the 2003 National Research Council Guidelines for the Care and 
Use of Mammals in Neuroscience and Behavioral Research and were approved by the Animal 
Care and Use Committee of Wake Forest University. Environmental enrichment was provided 
as outlined in the Animal Care and Use Committee of Wake Forest University Non-Human 
Primate Environmental Enrichment Plan. 
 
Food-reinforced responding.  Monkeys were trained under a reinforcement schedule in which 
50 responses on the left lever resulted in delivery of one food pellet, i.e., an FR 50 schedule of 
reinforcement. Under this schedule, white stimulus lights above the left lever were illuminated 
and 50 responses resulted in food pellet delivery, extinguishing of white lights and illumination of 
red stimulus lights for 10 sec, followed by a 10-sec timeout (TO) period during which no lights 
were illuminated and responding had no scheduled consequences. Sessions began at 
approximately 8:30 a.m. each day and lasted for approximately 23 hours or until the maximum 
number of allowed food reinforcers was earned. Thus only food was available from 8:30 am to 
3:00 pm when the self-administration session began (see below). At that point, food and 
cocaine were concurrently available if the monkey had not yet received the maximum number of 
pellets. The maximum number of pellets that could be earned was determined for each monkey 
as that required to provide enough food to maintain body weight, measured at least monthly, at 
approximately 95% of free-feeding levels. When monkeys earned fewer than the maximum 
number of food pellets, supplementary food (LabDiet Monkey Chow #5045) was given at 





level. Target food amounts for the monkeys in the present study ranged from 110 to 180 g. 
Weights did not change more than 4% during the course of this study. 
 
Cocaine self-administration. Monkeys self-administered (-)cocaine HCl (National Institute on 
Drug Abuse, Bethesda, MD, dissolved in sterile 0.9% saline) under a PR schedule of 
reinforcement in sessions that began at 3:00 p.m. each day. Under this schedule, white stimulus 
lights were illuminated above the right lever and 50 responses on that lever resulted in the first 
injection of the maintenance dose of cocaine (0.03 mg/kg per injection in approximately 1.5 ml 
over 10 seconds), extinguishing of white lights and illumination of red stimulus lights for 10 sec, 
followed by a 10-min TO. The response requirement for subsequent injections was determined 
by the equation used by Richardson and Roberts (1996): ratio = [5 x e(R x 0.2)] – 5, where e is the 
mathematical constant and R is equal to the reinforcer number. For the present studies, the first 
response requirement (50 responses) corresponds to the 12th value given by this equation and 
was followed by 62, 77, 95, 117, 144, 177, 218, 267, 328, 402, 492, 602, 737, 901, 1102, etc. 
Sessions ended when 2 hours elapsed without an injection. Initially, 0.03 mg/kg cocaine was 
made available in evening PR sessions until responding stabilized (3 consecutive days on which 
the number of injections were within 2 of the 3-day mean, with no upward or downward tend). 
Subsequently, other doses of cocaine (0.003-0.56 mg/kg per injection) were substituted in 
mixed order for the maintenance dose for at least four days and until the number of injections 
earned stabilized. 
 
Chronic MPD treatment. Following the generation of baseline dose-effect curves, 0.03 mg/kg 
cocaine was made available in evening PR sessions until responding stabilized, at which point 
chronic MPD treatment was initiated. When intravenous (±)-MPD (NIDA, Bethesda, MD) 
treatment was being studied (0.003-0.056 mg/kg/hour; N=3), at approximately 8:30 a.m., the 





Instrument Co., Vernon Hills, IL) outside the chamber and MPD was infused at a rate of 0.5 
ml/hr such that monkeys received an initial dose of 0.003 or 0.01 mg/kg/hr. Food-reinforced 
responding was studied throughout treatment. On the seventh day, the solution being infused 
was changed from MPD to saline at approximately noon. This time was selected because it 
takes approximately three hours to infuse the residual MPD in the catheter (~1.2 ml). Thus, 
MPD continued to be infused until approximately 2:55 p.m., at which time the catheter was filled 
with the maintenance dose of cocaine. This procedure minimized the amount of MPD infused as 
a bolus when the catheter was filled with cocaine immediately before the start of the self-
administration session. At 3:00 p.m., the maintenance dose of cocaine was made available for 
self-administration under the PR schedule of reinforcement, signaled by illumination of the white 
stimulus lights above the right lever. Thus, MPD treatment continued until the start of the 
cocaine self-administration session. At approximately 8:30 a.m. on the next day, the catheter 
was flushed with heparin/saline solution, after which administration of the same dose of MPD 
was continued. When MPD was administered orally (1.0-9.0 mg/kg, b.i.d.; N=4), MPD was 
dissolved in sterile 0.9% saline solution at a concentration of 100 mg/ml and the required 
volume was mixed with mashed banana in a small paper cup and given to the monkey at 
approximately 8:00 a.m. and 2:45 p.m.; the monkey was observed to assure that all the banana 
had been consumed. During MPD treatment, monkeys were observed for several minutes each 
morning and non-systematically throughout the day and any observed locomotor activation, 
agitation, stereotypies or other unconditioned behavioral effects were noted. 
 
This procedure (making the maintenance dose of cocaine available for one session) was 
repeated on day 14. If, at that time, the number of cocaine injections were decreased from 
baseline by approximately 30% or more, treatment was continued another 14 days. If an 
increase or no decrease in cocaine self-administration had been observed on day 14, or if 





effects of the higher dose of MPD were similarly assessed. If treatment with this dose had no 
effect or if tolerance developed, the dose was increased further. When a dose was reached that 
either decreased the number of cocaine injections after ~28 days or produced behaviorally 
disruptive effects, the cocaine dose-response curve was redetermined by making a single dose 
available for one day at 3-day intervals while oral MPD treatment was continued. Next, MPD 
treatment was discontinued, and over the next four months the cocaine dose-effect curve was 
again determined in the absence of MPD as described above for the initial determination. That 
is, doses were substituted in mixed order for the maintenance cocaine dose for at least four 
days and until the number of injections earned had stabilized. 
 
Data Analysis.  The dependent variable of primary interest was the number of cocaine 
injections earned under the PR schedule of reinforcement. In addition, the number of food 
reinforcers received was recorded in hourly bins. Because individual differences in sensitivity to 




Baseline food- and cocaine-reinforced responding.  Under baseline conditions, monkeys 
earned all available food pellets, typically within the first two hours of availability with the 
exception of subject R-1525 who earned approximately half his ration in the first two hours. In 
cocaine self-administration sessions, the number of injections received increased significantly 
as a function of the available cocaine dose, up to 0.3 mg/kg cocaine, in all monkeys (Fig. 1, 
closed symbols). In all cases, the cocaine self-administration session had concluded by 7:30 am 






Effects of intravenous MPD treatment on food- and cocaine-reinforced responding. 
During intravenous MPD administration, unconditioned effects of MPD were noted on several 
days indicated with asterisks along the abscissa in Fig. 2, particularly in R-1429. Such effects 
included self- or experimenter-directed aggression (e.g., threats, picking or biting the leg and/or 
harness) as well as increased locomotion. In R-1429, treatment with 0.03 mg/kg/hr MPD 
produced an ~35% decrease in the number of injections earned after one week that was 
maintained at the end of the second week. When the MPD dose was increased to 0.056 
mg/kg/hr, increased locomotion was observed. A test session did not occur at Day 7 because 
the monkey had disconnected the needle from the VAP and it was necessary to sedate him to 
replace the needle. When tested on Day 14, however, there was a decrease in cocaine self-
administration to which tolerance developed over the first month. At approximately 5 weeks of 
treatment with this dose, food- and cocaine-maintained responding decreased precipitously. 
During this time, the monkey was often lying down in his cage, would not take treats from 
experimenters and did not eat Monkey Chow placed in his cage. For these health-related 
reasons, MPD treatment was discontinued. Food-maintained responding recovered quickly to 
baseline levels. Due to the experience with this monkey, doses higher than 0.056 mg/kg/hr were 
not tested in the other two subjects.  
 
In R-1552, cocaine self-administration was increased transiently during treatment with the 
lowest dose of MPD (0.01 mg/kg/hr). This effect dissipated after approximately three weeks. 
Treatment with a higher dose did not affect cocaine self-administration, but altered the pattern of 
food-maintained responding. Although the monkey received his total allotment of food pellets 
per day on almost every day, he tended to earn these pellets throughout a greater portion of the 
day, as is evidenced by the decreased number of pellets earned in the first two hours of the 
session (dotted lines in Fig. 2). Treatment with the highest MPD dose also did not alter cocaine-





the catheter became twisted and disconnected from the syringe pump. In contrast to the 
disruptive effects and inability of intravenous MPD to persistently decrease cocaine self-
administration in R-1429 and R-1552, results of i.v. MPD treatment were more selective for 
cocaine self-administration in comparison to food-maintained responding in R-1550 (Fig. 2). 
MPD treatment in this monkey produced a dose-related decrease in the number of cocaine 
injections earned in the absence of any disruption in food-maintained responding and only one 
occurrence of increased locomotion. The maximum decrease in the number of cocaine 
injections received was approximately 50% and appeared to be consistent over time, i.e., there 
was no trend towards an increasing effect or tolerance during treatment. Note that data for Day 
7 of treatment with 0.01 mg/kg/hr MPD have been excluded from the graphs for R-1552 and R-
1550. Monkeys’ responding was disrupted due to the presence of unfamiliar personnel in the 
laboratory on this day. 
 
Effects of oral MPD treatment on food- and cocaine-reinforced responding. In two 
monkeys (R-1552 and R-1550) oral administration of MPD began immediately after treatment 
with i.v. 0.056 mg/kg/hr MPD was completed. Oral MPD treatment was also tested in R-1548 
and R-1525 who had not received MPD intravenously. In R-1552, similar to what was observed 
during i.v. treatment, lower doses of oral MPD resulted in transient increases in cocaine self-
administration (Fig. 3). In general, however, no persistent effects were observed up to a dose of 
4.5 mg/kg, b.i.d. in any of the four monkeys (Fig 3). In R-1552, treatment with 6.0 mg/kg MPD, 
b.i.d, resulted in a decrease in the number of cocaine injections received under the PR schedule 
that persisted up to 4 weeks of treatment. There was no decrease in the total number of food 
reinforcers earned at this or any MPD dose in R-1552. However, similar to the effects of 
continuous i.v. treatment, twice-daily oral MPD treatment altered the pattern of food-maintained 
responding such that fewer pellets were earned in the first two hours of availability (dotted line in 






Effects of oral MPD in R-1550 differed from those observed with intravenous MPD. Whereas 
continuous i.v. treatment decreased cocaine self-administration, twice-daily treatment with 9.0 
mg/kg MPD increased the number of cocaine injections earned under the PR schedule. No 
lasting effects were observed with lower doses. As seen during i.v. treatment, there was no 
disruption in the number or pattern of food pellets earned. Similarly, in R-1525, only increases in 
self-administration were observed with higher MPD doses (6.0 and 9.0 mg/kg, b.i.d.) In this 
monkey, MPD treatment caused disruptions in both total food reinforcers earned and in the 
pattern of food-maintained responding across the day. Finally, in R-1548, the highest MPD dose 
(9.0 mg/kg, b.i.d.) produced a small but sustained decrease in cocaine-maintained responding. 
Disruption of the pattern of food-maintained responding by oral MPD was dependent on the 
MPD dose in this monkey. 
 
Redetermination of dose-effect curves during oral MPD treatment. Once a dose of MPD 
was found that either decreased cocaine self-administration for at least 28 days or when 9.0 
mg/kg, p.o., b.i.d. was reached, additional cocaine doses were made available for a single self-
administration session at 3-day intervals until a complete dose-effect curve was determined. In 
R-1552, in whom MPD treatment decreased self-administration of 0.03 mg/kg per injection 
cocaine, the entire cocaine dose-effect curve was shifted downward (Fig. 1, open circles). In R-
1548, intake of a low cocaine dose was increased although fewer injections of a higher dose 
(0.1 mg/kg) were received; other points on the dose-effect curve were not different from the 
baseline curve. In the two monkeys in whom the self-administration of the maintenance dose of 
cocaine was increased by MPD (R-1525 and R-1550), the low end of the cocaine dose-effect 






Cocaine self-administration after termination of MPD treatment. Once cocaine dose-effect 
curves had been re-determined during MPD administration, MPD treatment was terminated. 
Food-maintained responding continued to be measured daily, and monkeys were allowed 
access to the maintenance dose of cocaine (0.03 mg/kg per injection) under the PR schedule. 
Over the next several months, cocaine doses were substituted for the maintenance dose of 
cocaine until a dose-effect curve was again completed. In general, dose-effect curves only 
partially shifted back towards baseline (open squares, Fig. 1), despite that several weeks had 
passed since termination of MPD treatment.  
 
DISCUSSION 
Drugs that interact with the DA transporter have received much attention as potential 
pharmacotherapies for cocaine abuse due to the importance of DA in mediating the abuse-
related behavioral effects of cocaine. To date, however, substantial clinical evidence for the 
effectiveness of any such compound is lacking, with the exception of d-amphetamine (e.g., 
Grabowski et al., 2004), a DA and NE releaser whose potential as a medication is compromised 
by its high abuse liability (see Mariani and Levin, 2012). The primary goal of the present studies 
was to assess the therapeutic potential of the DA uptake inhibitor MPD as a medication for 
cocaine abuse. A unique cocaine self-administration procedure was used which was designed 
to reflect many clinically relevant aspects of cocaine use and medication treatment (Czoty et al., 
2011). For example, the present studies examined chronic oral treatment in cocaine-
experienced monkeys using a PR schedule. Cocaine self-administration was suspended during 
the first week of treatment to model the frequent (though not universal) clinical situation in which 
a cocaine addict is able to abstain from using cocaine for a brief period of time during the initial 
phase of treatment due to hospitalization, incarceration or motivation to remain abstinent when 
starting treatment. Each monkey’s response to treatment was monitored individually and 





individual’s response (i.e., a single-subject design, cf. Ator and Griffiths, 2003). Finally, food-
maintained responding along with close observation of the animals’ appearance and behavior 
provided an index of potential side effects. 
In the present study, although some reductions in cocaine self-administration were 
observed in some subjects, neither chronic intravenous nor chronic oral treatment with MPD 
exhibited an encouraging profile with respect to potential as a medication for cocaine abuse. 
When administered intravenously to three monkeys, MPD decreased cocaine self-
administration in one monkey, but treatment had to be discontinued in two monkeys due to 
adverse health and behavioral effects that subsided almost immediately upon cessation of MPD 
administration. These effects included agitation, heightened aggression, disruption of the 
pattern of food maintained responding and, in one case, a reduction in total food pellets 
consumed per 24 hours. These data can be interpreted to suggest that chronic MPD treatment 
(at least by the i.v. route) would be expected to produce severe side effects that would limit 
compliance and perhaps cause adverse health effects in patients. 
The transition to oral administration of MPD was associated with a much lower rate of 
such effects. Over several months in four subjects, only one instance of increased locomotion 
was observed, with no instances of agitation or aggression and no other detrimental effects to 
monkeys’ health. MPD did, however, reduce the overall number of food reinforcers earned in 
one monkey, and disrupted the pattern of food-maintained responding in three of four subjects. 
These effects on food-maintained responding are not in and of themselves necessarily 
discouraging (see Mello and Negus, 1996). In our previous studies with d-amphetamine using 
this model (Czoty et al., 2011), decreases in the total number of food reinforcers earned were 
commonly observed upon increasing the treatment dose of d-amphetamine. However, in every 
case tolerance developed to the effects of d-amphetamine on food-maintained responding while 
decreases in cocaine self-administration persisted (see also Negus and Mello, 2003). In the 





(R-1548), and the monkey whose food-maintained responding was unaffected by MPD showed 
an increase in cocaine self-administration. Taken together, it is evident that, although oral MPD 
treatment was better tolerated than chronic intravenous administration, some disruption was 
observed that might suggest lasting side effects. Of greater concern is the observation that 
chronic MPD administration increased cocaine self-administration in two monkeys, in 
accordance with data in rats (Hiranita et al., 2009), and that decreases in self-administration of 
the maintenance dose of cocaine in the other two subjects were, at most, partial. 
Once the MPD treatment dose either decreased self-administration of 0.03 mg/kg 
cocaine (6.0 mg/kg, b.i.d. in R-1552) or reached the highest dose we tested (9.0 mg/kg, b.i.d.), 
treatment with that MPD dose was continued and other doses of cocaine were tested at 3-day 
intervals. In this manner, a cocaine dose-effect curve was re-determined to better characterize 
the effects of MPD on the reinforcing effects of cocaine. In the subject whose self-administration 
was decreased by oral MPD (R-1552), the entire dose-effect curve was shifted downward. The 
other three subjects self-administered more injections of lower cocaine doses compared to 
baseline; the higher end of the curve was, for the most part, similar to baseline levels of self-
administration. Strikingly, when the dose-effect curve was again re-determined during the four 
months after MPD treatment had been discontinued, dose-effect curves had still not fully 
recovered to baseline. Nonetheless, regardless of the direction of effects of MPD on cocaine 
self-administration, they persisted for several weeks after MPD administration had concluded. 
Perhaps the most surprising aspect of these studies was that the doses that affected 
cocaine self-administration (6.0 - 9.0 mg/kg, b.i.d.) were substantially higher than those 
considered safe in humans. For example, the highest dose tested in human studies was 60 
mg/day (Collins et al., 2006; Levin et al., 2007), which is less than 1 mg/kg in an average-sized 
human. Doses necessary to observe effects in the present study reached 12-18 mg/kg per day, 
much higher than in the aforementioned studies and higher than doses used to treat adult 





2010). One reason for this difference may be that, unlike the present studies, clinical studies 
have used sustained-release formulations. We attempted to mimic this method of MPD delivery 
as much as possible by using continuous intravenous infusion but found that this approach was 
associated with a relatively high rate of adverse effects in two monkeys. Another implication is 
that the (lower) doses in the present study, which best approximate those used clinically, have 
no effect on self-administration. The necessity to use higher doses in the present study in 
monkeys may also explain why rates of adverse effects seen in these monkeys were relatively 
high compared to the few adverse effects observed in most studies in humans (e.g. Grabowski 
et al., 1997). 
The differences in effects of d-amphetamine and MPD observed using this procedure 
adds to a growing set of data suggesting that drugs that serve as substrates for DA and NE 
transporters (i.e., monoamine releasers) may be more suitable medications for cocaine 
dependence than drugs that inhibit DA and NE uptake by binding to transporters. Although the 
DA-selective uptake inhibitor GBR 12909 and cocaine itself have been shown to selectively 
decrease cocaine- versus food-maintained responding (Glowa et al., 1995a,b; Glowa and 
Fantegrossi, 1997), this effect is less evident under lean conditions of reinforcement (i.e., lower 
cocaine doses and higher response requirements; Stafford et al., 2000). Chronic treatment with 
other monoamine transporter inhibitors including mazindol, RTI-112, RTI-113 and indantraline 
resulted in reductions in both food- and cocaine-maintained responding (Kleven and 
Woolverton, 1993; Negus et al., 1999, 2009a). On the other hand, amphetamine-like DA/NE 
releasers have shown more consistent selectivity in their behavioral effects (e.g., Negus et al., 
2007, 2009b). Although the mechanisms underlying the behavioral differences between 
releasers and uptake inhibitors remain to be elucidated, pharmacotherapeutic approaches that 
reduce the abuse liability of amphetamine-like compounds, such as pro-drugs (e.g., 





for development of “agonist” medications for cocaine dependence than DA/NE transporter 
inhibitors. 
In summary, neither intravenous nor oral MPD treatment reliably decreased cocaine self-
administration in the absence of behaviorally disruptive effects, using a paradigm designed to 
incorporate clinically relevant aspects of cocaine use and pharmacotherapeutic treatment. 
Clearly these adjustments do not completely recapitulate the clinical condition in that cocaine 
availability was limited and abstinence was forced (rather than voluntary) and occurred 
throughout the testing period. Moreover there are many other aspects that have not been, and 
possibly cannot be, incorporated into animal models (e.g., uniquely human negative 
consequences of drug use on employment and progressive psychiatric consequences). 
Nonetheless, it is hoped that enhancing the face value of the procedure as a model of drug 
abuse and pharmacotherapy will also increase its predictive validity. The results of the present 
studies are concordant with clinical findings and suggest that MPD would not be a safe and 
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Figure 1. Dose-effect curves for cocaine self-administration before (filled circles), during (open 
circles) and after (open squares) oral MPD treatment in four monkeys. Each point on the 
“baseline” and “post-methylphenidate” curves is the mean of the last three days of availability of 
a cocaine dose or saline; data for the “during methylphenidate” curve are from single-session 
tests of that cocaine dose. When a cocaine dose or saline was made available on more than 
one occasion, error bars indicate the standard error of the mean. Ordinates: number of cocaine 
injections earned; abscissae, available cocaine dose. 
 
Figure 2. Cocaine self-administration and food-maintained responding during intravenous MPD 
treatment in individual monkeys. Left ordinates: number of cocaine injections received; right 
ordinates: number of food reinforcers earned; abscissae: day of exposure to each MPD dose, 
which is indicated across the top of each panel. The point above BL represents mean (±SEM) 
number of injections earned on the three days prior to initiation of MPD treatment. The dashed 
line in each graph indicated the mean number of injections received under baseline conditions 
(i.e., prior to MPD treatment). The dotted line in each graph represents the number of pellets 
earned in the first 2 hr of food pellet availability. 
 
Figure 3. Cocaine self-administration and food-maintained responding during oral MPD 
treatment in individual monkeys. Otherwise, as in Fig. 2. 
 
  



